Sessions
Why So Shy? Implementing Disruptive Technologies with Confidence in Cell Therapy
Technology, Disruptive Innovation and Partnerships that are Revolutionizing How Medicines Are Made
Overcoming Scale Up Process Development Challenges for Pluripotent Stem Cell Derived Therapies
Future-Proofing Cell Therapy Production
Add It Up: 3 Things to Consider for Capacity Expansion
Unlocking the Potential of Advanced Therapies Through Collaborations
Why So Shy? Implementing Disruptive Technologies with Confidence in Cell Therapy
SPONSORED BY
Why So Shy? Implementing Disruptive Technologies with Confidence in Cell Therapy
Introducing new technologies into a cell therapy manufacturing process presents multiple potential benefits, risks and cost. Understanding the critical decisions points that companies face as they scale their production and move towards commercialization can help manufacturers introduce disruptive technologies appropriately.
This panel will discuss:
- Evaluation criteria for bringing in new technology
- The factors involved in aligning platform and process development
- Bringing disruptive technologies into the process in the context of clinical timelines
- When is it beneficial to use something in PD before it is GMP ready?
Moderator
David Hodl, Head of Business Development, Invetech
Panellists
Matthew Li, Associate Director, Head of Cell Therapy Manufacturing Innovation, Vor Biopharma
Fabio Fachin, Head Cell Therapy Process Development, Automation and Digital Technologies, Takeda
Nicholas Ostrout, Senior Director Commercial Strategy and Implementation, Lonza
Speakers
